在验证了与拉莫三嗪普通片剂的生物等效性后，拉莫三嗪口腔崩解片被批准，由葛兰素史克与尤兰德EurandNV合作开发。
These new disintegrating tablets were approved on the basis of their demonstrated bioequivalence to Lamictal tablets and were developed in collaboration with Eurand NV.
在验证了与拉莫三嗪普通片剂的生物等效性后，拉莫三嗪口腔崩解片被批准，由葛兰素史克与尤兰德EurandNV合作开发。
These new disintegrating tablets were approved on the basis of their demonstrated bioequivalence to Lamictal tablets and were developed in collaboration with Eurand NV.
应用推荐